A Phase 1, Open-label, Dose-Ascending Study to Evaluate the Safety and Tolerability of the Therapeutic Radiopharmaceutical 131I-MIP-1095 for the Treatment of Metastatic Castration-Resistant Prostate Cancer.

Laccetti 2023 · Laccetti Andrew L, Bodei Lisa, O'Donoghue Joseph A, et al. · Clinical nuclear medicine · 2023